Relay Therapeutics (RLAY) Earnings Analysis
Relay Therapeutics (RLAY) next reports earnings on 2026-08-06, consensus EPS -0.41 USD. Last quarter (2026-02-26) it beat with EPS -0.32 USD vs -0.38 USD est (+15.8%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -12.27.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RLAY next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.41 USD |
| Revenue estimate | 0.00B |
RLAY earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | -0.32 USD | -0.38 USD | +15.8% | Beat |
| 2025-11-06 | -0.43 USD | -0.39 USD | -10.3% | Miss |
| 2025-08-07 | -0.41 USD | -0.49 USD | +16.3% | Beat |
| 2025-05-05 | -0.46 USD | -0.5 USD | +8% | Beat |
| 2025-02-26 | -0.45 USD | -0.57 USD | +21.1% | Beat |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
RLAY valuation and analyst view
| Trailing P/E | -12.27 |
|---|---|
| Trailing EPS | -1.5163 USD |
| Price / book | 5.40 |
| Dividend yield | 0.00% |
| Market cap | 3.37B |
| Analyst consensus | Buy (15 buy / 0 hold / 0 sell) |
| Avg price target | 25.3 USD |
Related research pages
Frequently asked questions
When is Relay Therapeutics (RLAY)'s next earnings date?
Relay Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.41 USD and revenue estimate of 0.00B.
Did RLAY beat earnings last quarter?
In its 2026-02-26 report, RLAY posted EPS of -0.32 USD versus a -0.38 USD estimate — a beat of 15.8%.
What is RLAY's earnings track record?
Over the last 5 reported quarters with consensus data, RLAY beat estimates 4 times (80%).
What is RLAY's current P/E ratio and EPS?
RLAY trades at a trailing P/E of -12.27 on trailing EPS of -1.5162986297788017 USD.
What do analysts rate RLAY?
Analyst consensus is "Buy" across 15 ratings (1 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 25.3 USD.